Ertabresib (Standard)
Ertabresib (Standard) (INCB-057643 (Standard)) is the analytical standard of Ertabresib (HY-111485). This product is intended for research and analytical applications. Ertabresib (INCB-057643) is an orally active BET protein inhibitor. Ertabresib blocks gene transcription by targeting the BET protein family, induces cell cycle arrest and apoptosis by downregulating proto-oncogenes such as c-MYC, and additionally reduces the expression of FOXP3 and PD-L1 to improve the immune microenvironment. It also exerts synergistic effects and overcomes drug resistance when combined with chemotherapy and XPO1 inhibitors. Ertabresib can be used in research related to high-grade B-cell lymphoma with MYC and BCL2 rearrangements, pancreatic cancer, pancreatitis, and metastatic castration-resistant prostate cancer.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 1820889-23-3
- Fòrmula: C20H21N3O5S
- Peso molecular:415.46
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
Product Information
Information
Aplicación
The compound is the grade of analytical standard, which is the reference standard supplied assay. It is commonly used in qualitative, quantitative and methodological research experiments in HPLC, GC and MS.
Chemical Information
-
No. CAS 1820889-23-3
-
Peso molecular 415.46
-
Fòrmula C20H21N3O5S
-
SMILES
O=C1C(C)(C)OC2=C(C3=CN(C)C(C4=C3C=CN4)=O)C=C(S(=O)(C)=O)C=C2N1C
-
Synonyms
INCB-057643 (Standard)
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- Ertabresib (Standard)
- 1820889-23-3
- INCB-057643 (Standard)
- Reference Standards
- Epigenetic Reader Domain
- Apoptosis
- c-Myc
- FOXP
- PD-1/PD-L1
- TP53
- pancreatitis
- high-grade B-cell lymphoma with MYC and BCL2 rearrangements
- BET protein
- pancreatic cancer
- RAW 264.7 macrophage-like cells
- MYC
- CD4 T cells
- BCL2
- metastatic castration-resistant prostate cancer
- Inhibitor
- inhibitor
- inhibit